NOVN Novan Inc

NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN)

NEW ORLEANS--(BUSINESS WIRE)--

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until January 2, 2018 to file lead plaintiff applications in a securities class action lawsuit against Novan, Inc. (NasdaqGM: NOVN). Investor losses must relate to purchases of the Company’s shares between the expanded period of September 26, 2016 and August 1, 2017 (the “Class Period”) and/or pursuant to its September 26, 2016 initial public offering (“IPO”). This action is pending in the United States District Court for the Middle District of North Carolina.

What You May Do

If you purchased shares of Novan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nasdaqgm-novn/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by January 2, 2018.

About Kahn Swick & Foti, LLC

KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

EN
30/12/2017

Underlying

NOVNNovan Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novan Inc

 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Enters into Agreement to Sell Substantially All of its Assets, i...

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – A...

July 17, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockh...

Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current focus, position...

June 5, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Focuses Strategic Direction and Announces Restructuring

Novan Focuses Strategic Direction and Announces Restructuring – Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to ...

May 31, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan Reports First Quarter 2023 Financial Results and Provides Corpor...

Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today...

May 15, 2023 1 EN
 PRESS RELEASE
Free
NOVN NOVAN INC

Novan to Report First Quarter 2023 Financial Results on May 15, 2023

Novan to Report First Quarter 2023 Financial Results on May 15, 2023 DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested...

May 8, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch